טוען...
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®(MMX®)) for active, mild-to-moderate ulcerative colitis
BACKGROUND: Cortiment®(MMX®) (budesonide MMX®) is currently approved for the induction of remission in mild-to-moderate ulcerative colitis (UC) patients when 5-ASA treatment is not sufficient. Data in real-life settings are lacking. METHODS: This was a multicentre observational prospective cohort st...
שמור ב:
| הוצא לאור ב: | United European Gastroenterol J |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6826527/ https://ncbi.nlm.nih.gov/pubmed/31700630 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2050640619864848 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|